Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy

Autoimmunity Reviews

Volumn 12, Issue 7, 2013, Pages 709-716

  Cipriani, Paola ^a   Carubbi, Francesco ^a   Liakouli, Vasiliki ^a   Marrelli, Alessandra ^a   Perricone, Carlo ^b   Perricone, Roberto ^c   Alesse, Edoardo ^a   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Autoimmune diseases; Hematopoietic stem cells; Mesenchymal stem cells; Stem cell transplantation

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; PENICILLAMINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; JUVENILE RHEUMATOID ARTHRITIS; JUVENILE SYSTEMIC SCLEROSIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SAFETY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THERAPY EFFECT; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84877806000     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.10.004     Document Type: Review

References (106)

1. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferringthe microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17:331-340.
2. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
3. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
4. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999, 96:10711-10716.
5. Rose R.A., Jiang H., Wang X., Helke S., Tsoporis J.N., Gong N., et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 2008, 26:2884-2892.
6. Bang O.Y., Lee J.S., Lee P.H., Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882.
7. Lee P.H., Kim J.W., Bang O.Y., Ahn Y.H., Joo I.S., Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2007, 83:723-730.
8. Sage E.K., Loebinger M.R., Polakand J., Janes S.M. The role of bone marrow-derived stem cells in lung regeneration and repair, stembook 2008, Harvard Stem Cell Institute, Cambridge.
9. Zhao D.C., Lei J.X., Chen R., Yu W.H., Zhang X.M., Li S.N., et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 2005, 11:3431-3440.
10. Assis A.C., Carvalho J.L., Jacoby B.A., Ferreira R.L., Castanheira P., Diniz S.O., et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the in farcted heart. Cell Transplant 2010, 19:219-230.
11. Qian H., Yang H., Xu W., Yan Y., Chen Q., Zhu W., et al. Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med 2008, 22:325-332.
12. Miller R.H., Bai L., Lennon D.P., Caplan A.I. The potential of mesenchymal stem cells for neural repair. Discov Med 2010, 9:236-242.
13. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
14. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
15. Ben -Ami E., Berrih-Aknin S., Miller A.C. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 2011, 10:410-415.
16. Bombardier D.D.Gladman, Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640.
17. Zakian V.A. Telomeres: beginning to understand the end. Science 1995, 270:1601-1607.
18. Colter D.C., Sekiya I., Prockop D.J. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 2001, 98:7841-7845.
19. Baxter M.A., Wynn R.F., Jowitt S.N., Wraith J.E., Fairbairn L.J., Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004, 22:675-682.
20. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953.
21. Zimmermann S., Voss M., Kaiser S., Kapp U., Waller C.F., Martens U.M. Lack of telomerase activity in human mesenchymal stem cells. Leukemia 2003, 17:1146-1149.
22. Sethe S., Scutt A., Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006, 5:91-116.
23. Kurosaka D., Yasuda J., Yoshida K., Yoneda A., Yasuda C., Kingetsu I., et al. Abnormal telomerase activity and telomere length in T and B cells from patients with systemic lupus erythematosus. J Rheumatol 2006, 33:1102-1107.
24. Ohtsuka T., Yamakage A., Yamazaki S. The polymorphism of telomerase RNA component gene in patients with systemic sclerosis. Br J Dermatol 2002, 147:250-254.
25. Bocelli-Tyndall C., Bracci L., Spagnoli G., Braccini A., Bouchenaki M., Ceredig R., et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007, 46:403-408.
26. Lennon D.P., Caplan A.I. Isolation of human marrow-derived mesenchymal stem cells. Exp Hematol 2006, 34:1604-1605.
27. Bruder S.P., Jaiswal N., Haynesworth S.E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive sub cultivation and following cryopreservation. J Cell Biochem 1997, 64:278-294.
28. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
29. Sun L.Y., Zhang H.Y., Feng X.B., Hou Y.Y., Lu L.W., Fan L.M. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007, 16:121-128.
30. Dominici M., Paolucci P., Conte P., Horwitz E.M. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation 2009, 87(9 Suppl.):S36-S42.
31. Buron F., Perrin H., Malcus C., Héquet O., Thaunat O., Kholopp-Sarda M.N., et al. Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells. Transplant Proc 2009, 41:3347-3352.
32. van Laar J.M., Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45:1187-1193.
33. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
34. Burt R.K., Slavin S., Burns W.H., Marmont A.M. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure?. Blood 2002, 99:768-784.
35. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
36. Gordon D., Pavlovska G., Glover C.P., Uney J.B., Wraith D., Scolding N.J. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008, 448:71-73.
37. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009, 182:5994-6002.
38. Constantin G., Marconi S., Rossi B., Angiari S., Calderan L., Anghileri E., et al. Adipose derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009, 27:2624-2635.
39. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57:1192-1203.
40. Lanz T.V., Opitz C.A., Ho P.P., Agrawal A., Lutz C., Weller M., et al. Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev 2010, 19:657-668.
41. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus host disease: a phase II study. Lancet 2008, 371:1579-1586.
42. Duijvestein M., Vos A.C., Roelofs H., Wildenber M.E., Wendrich B.B., Verspaget H.W., et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010, 59:1662-1669.
43. Liang J., Zhang H., Hua B., Wang H., Lu L., Shi S., et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010, 69(8):1423-1429.
44. Sun L., Wang D., Liang J., Zhang H., Feng X., Wang H., et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010, 62(8):2467-2475.
45. Gao J., Dennis J.E., Muzic R.F., Lundberg M., Caplan A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001, 169:12-20.
46. Barbash I.M., Chouraqui P., Baron J., Feinberg M.S., Etzion S., Tessone A., et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003, 108:863-868.
47. Kassis I., Grigoriadis N., Gowda-Kurkalli B., Mizrachi-Kol R., Ben-Hur T., Slavin S., et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008, 65:753-761.
48. Zhang J., Li Y., Chen J., Cui Y., Lu M., Elias S.B., et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005, 195:16-26.
49. Lanza C., Morando S., Voci A., Canesi L., Principato M.C., Serpero L.D., et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009, 110:1674-1684.
50. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006, 119:2204-2213.
51. Beltrami A.P., Cesselli D., Bergamin N., Marcon P., Rigo S., Puppato E., et al. Multipotent cells can be generated in vitro from several adult human organs (heart, liver, and bone marrow). Blood 2007, 110:3438-3446.
52. Covas D.T., Panepucci R.A., Fontes A.M., Silva W.A., Orellana M.D., Freitas M.C., et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 2008, 36:642-654.
53. Hegyi B., Sági B., Kovács J., Kiss J., Urbán V.S., Mészáros G., et al. Identical, similar or different? Learning about immunomodulatory function of mesenchymal stem cells isolated from various mouse tissues: bone marrow, spleen, thymus and aorta wall. Int Immunol 2010, 22:551-559.
54. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
55. Caplan A.I. All MSCs are pericytes?. Cell Stem Cell 2008, 3(3):229-230.
56. Sorrell J.M., Baber M.A., Caplan A.I. Influence of adult mesenchymal stem cells on in vitro vascular formation. Tissue 2009, 15(7):1751-1761.
57. da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
58. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
59. Nie Y., Lau C.S., Lie A.K.W., Chan G.C.F., Mok M.Y. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010, 19:850-859.
60. Kastrinaki M.C., Sidiropoulos P., Roche S., Ringe J., Lehmann S., Kritikos H., et al. Functional, molecular and proteomic characterization of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 2008, 67:741-749.
61. Zhao Y., Mazzone T. Human cord blood stem cells and the journey to a cure for type 1 diabetes. Autoimmun Rev 2010, 10:103-107.
62. Colmegna I., Diaz-Borjon A., Fujii H., Schaefer L., Goronzy J.J., Weyand C.M. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum 2008, 58:990-1000.
63. Challen G.A., Boles N.C., Chambers S.M., Goodell M.A. Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010, 6:265-278.
64. Beerman I., Bhattacharya D., Zandi S., Sigvardsson M., Weissman I.L., Bryder D., et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci USA 2010, 107:5465-5470.
65. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
66. Sonoda Y. Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection. J Autoimmun 2008, 30:136-144.
67. Gan B., DePinho R.A. Mtorc1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 2009, 8:1003-1006.
68. Massberg S., Schaerli P., Knezevic-Maramica I., Köllnberger M., Tubo N., Moseman E.A., et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007, 131:994-1008.
69. Castro-Malaspina H., Harris R.E., Gajewski J., Ramsay N., Collins R., Dharan B., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002, 99:1943-1951.
70. Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
71. Song Z., Ju Z., Rudolph K.L. Cell intrinsic and extrinsic mechanisms of stem cell aging depend on telomere status. Exp Gerontol 2009, 44:75-82.
72. Tempescul A., Ianotto J.C., Hardy E., Quivoron F., Petrov L., Berthou C. Peripheral blood stem cell collection in elderly patients. Ann Hematol 2010, 89:317-321.
73. Ogawa T., Kitagawa M., Hirokawa K. Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. Mech Ageing Dev 2000, 117:57-68.
74. Offner F., Kerre T., De Smedt M., Plum J. Bone marrow CD34 cells generate fewer T cells in vitro with increasing age and following chemotherapy. Br J Haematol 1999, 104:801-808.
75. Burt R.K., Testor A., Graig R., Cohen B., Suffit R., Barr W. Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned?. J Autoimmun 2008, 30:116-120.
76. Deane S., Meyers F.J., Gershwin M.E. On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. J Autoimmun 2008, 30:180-196.
77. Moore J., Tyndall A., Brooks P. Stem cells in the aetiopathogenesis and therapy of rheumatic disease. Best Pract Res Clin Rheumatol 2001, 15(5):711-726.
78. Levite M., Zinger H., Mozes E., Reisner Y. Systemic lupus erythematosus-related autoantibody production in mice is determined by bone marrow-derived cells. Bone Marrow Transplant 1993, 12:179-183.
79. Otsuka T., Okamura S., Harada M. Multipotenthemopoietic progenitor cells in patients with systemic lupus erythematosus. J Rheumatol 1988, 15:1085-1090.
80. Colmegna I., Weyand C.M. Haematopoietic stem and progenitor cells in rheumatoid arthritis. Rheumatology 2011, 50:252-260.
81. Tomita T., Shimaoka Y., Kashiwagi N. Enhanced expression of CD14 antigen on myeloid lineage cells derived from the bone marrow of patients with severe rheumatoid arthritis. J Rheumatol 1997, 24:465-469.
82. + progenitor cells from rheumatoid arthritis patients support spontaneous transformation of peripheral blood B cells from healthy individuals. Rheumatol Int 2000, 19:153-159.
83. Doita M., Maeda S., Kawai K. Analysis of lymphocyte subsets of bone marrow in patients with rheumatoid arthritis by two colour immunofluorescence and flow cytometry. Ann Rheum Dis 1990, 49:168-171.
84. Koetz K., Bryl E., Spickschen K. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000, 97:1.
85. Shen Y., Ichino M., Nakazawa M., Minami M. CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response. J Invest Dermatol 2005, 124:1141-1148.
86. Matsushita T., Hasegawa M., Hamaguchi Y., Takehara K., Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006, 33:275-284.
87. Tsukamoto H., Nagafuji K., Horiuchi T., Mitoma H., Niiro H., Arinobu Y., et al. Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells. Rheumatology 2011, 50:944-952.
88. Farge D., Labopin M., Tyndall A., Fassas A., Mancardi G.L., Van Laar J., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010, 95(2):284-292.
89. Snowden J.A., Pearce R.M., Lee J., Kirkland K., Gilleece M., Veys P., et al. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. Br J Haematol 2012, 157(6):742-746.
90. Farge D., Marolleau J.P., Zohar S., Marjanovic Z., Cabane J., Mounier N., et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002, 119:726-739.
91. Vonk M.C., Marjanovic Z., van den Hoogen F.H., et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008, 67:98-104.
92. Englert H., Kirkham S., Moore J., Poon T.S., Katelaris C., McGill N., et al. Autologous stem cell transplantation in diff use scleroderma: impact on hand structure and function. Intern Med J 2008, 38:692-696.
93. Launay D., Marjanovic Z., de Bazelaire C., Florea L., Zohar S., Keshtmand H., et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. J Rheumatol 2009, 36:1460-1463.
94. Tsukamoto H., Nagafuji K., Horiuchi T., Miyamoto T., Aoki K., Takase K., et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006, 65:508-514.
95. Fleming J.N., Nash R.A., McLeod D.O., Fiorentino D.F., Shulman H.M., Connolly M.K., et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?. PLoS One 2008, 3:e1452.
96. Aschwanden M., Halter J.P., Walker U.A., Staub D., Tichelli A., Daikeler T., et al. Nail fold capillaroscopy diers widely between systemic sclerosis and chronic graft vs host disease of the skin. Rheumatology (Oxford) 2011, 50:1168-1169.
97. van Laar J.M., Farge D., Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005, 64:1515.
98. Craciunescu O.I., Steffey B.A., Kelsey C.R., Larrier N.A., Paarz-Largay C.J., Prosnitz R.G., et al. Int J Radiat Oncol Biol Phys 2011, 79(4):1248-1255.
99. Burt R.K., Shah S.J., Dill K., Grant T., Gheorghiade M., Schroeder J., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011, 6:498-506.
100. Foeldvari I., Zhavania M., Birdi N., Cuttica R.J., de Oliveira S.H.F., Dent P.B., et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multinational survey. Rheumatology 2000, 39:556-569.
101. Martini G., Foeldvari I., Russo R., Cuttica R., Eberhard A., Ravelli A., et al. Systemic sclerosis in childhood: clinical and immunological features of 153 patients in an international database. Arthritis Rheum 2006, 54:3971-3978.
102. Oyama Y., Barr W.G., Statkute L., Corbridge T., Gonda E.A., Jovanovic B., et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007, 40:549-555.
103. Marmont A.M., van Lint M.T., Gualandi F., Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997, 6(6):545-548.
104. Illei G.G., Cervera R., Burt R.K., Doria A., Hiepe F., Jayne D., et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis 2011, 70(12):2071-2074.
105. Bingham S.J., Moore J.J. Stem cell transplantation for autoimmune disorders Rheumatoid arthritis. Best Pract Res Clin Haematol 2004, 17(2):263-276.
106. Snowden J.A., Passweg J., Moore J.J., Milliken S., Cannell P., Van Laar J., et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004, 31(3):482-488.